Trial · NCT00441272
Pioglitazone to Treat Fatty Liver in People With HIV Infection
NCT00441272, Phase 2, Completed, National Institute of Allergy and Infectious Diseases (NIAID); results first posted 2010-02-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pioglitazone to Treat Fatty Liver in People With HIV Infection. Trials, record NCT00441272. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00441272
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pioglitazone to Treat Fatty Liver in People With HIV Infection
- NCT number
- NCT00441272
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 100 participants, actual
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- HIV Infections, Hepatic Steatosis, Insulin Resistance
- Interventions
- Pioglitazone
- First posted
- 2007-02-28
- Last updated
- 2010-02-19
- Results first posted
- 2010-02-19
- Limitations and caveats
- Early termination prior to enrollment leading to no analysis of enrolled participants receiving Pioglitazone or placebo.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hepatic Steatosis | 96 weeks | Evaluation of the safety and potential benefits of pioglitazone therapy on hepatic steatosis in HIV-infected men and women. |
| Secondary | Insulin Resistance | 48 weeks |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Hepatic Steatosis | 96 weeks | A total of 11 subjects enrolled into the study. 10 were determined to be ineligible during the screening as the Computerized tomography scan revealed a liver-to-spleen ratio \> 1 and one was determined ineligible due to concomitant medication use. | Hounsfeld units | MEAN |
| SECONDARY | Insulin Resistance | 48 weeks |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 25 | |
| Overall Study | STARTED | Pioglitazone 45mg/Day | 25 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | COMPLETED | Pioglitazone 45mg/Day | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 25 | |
| Overall Study | NOT COMPLETED | Pioglitazone 45mg/Day | 25 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Pioglitazone 45mg/Day | ||
| Total, other adverse events | Placebo | 0 | 0 |
| Total, other adverse events | Pioglitazone 45mg/Day | 0 | 0 |
| Total, serious adverse events | Placebo | 0 | 0 |
| Total, serious adverse events | Pioglitazone 45mg/Day | 0 | 0 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00441272
GET https://conductscience.org/api/trials/v1/NCT00441272/registered